

Biotech Capital.

Biotech Capital (BTC) - ASX Announcement

29 November 2016

Chairman's Address to Shareholders

Ladies and gentlemen,

We have made good progress over the last year in terms of our goal to reposition the company and lay the foundation for a new phase of growth. The company is now headquartered in Melbourne and we have established a strong operational presence in Sydney. We are very fortunate to have experienced management and Board of Directors and a highly supportive shareholder base.

As a registered Pooled Development Fund, our strategy is to make investments in high-growth, Australian life science companies, which are either at, or close to early revenues and which we consider will benefit from additional investment and business support. We are active in seeking out and evaluating only the most compelling opportunities and we remain disciplined with respect to our investment criteria. As we grow the organisation we are taking every opportunity to build a talented and diverse team, along with an exceptional business culture.

In April of this year we successfully acquired and integrated the Biointelect business, a Sydney-based advisory firm in the life science sector. With this acquisition, we acquired a highly credentialed team with a strong track record and an established client base.

In June, we recognised an opportunity to establish and invest in a finance and administration business, Bio101Group, which is dedicated to supporting SME's in the life science sector. Although at an early stage, we have already begun to realise the benefit of our two companies combining their business development efforts, as well as the back-office and administrative functions. Working closely with each other the Biointelect and Bio101 teams have even greater client reach and a more relevant and integrated service offering. Over the next 12 months we will continue to expand the range of professional services that we provide to biotech, medtech, pharma companies, venture capital firms and research institutes. This growth is expected to come from a combination of "build" and "buy" initiatives, i.e. from internal growth plans as well as through select acquisitions.


We recently established working alliances in the US and Europe, which we expect will assist us in identifying and realising additional opportunities within these countries. As we expand the service offering of the group and continue to build scale we are aggregating valuable industry capabilities and building capacity within the broader organisation. This is a deliberate strategy that in time will allow us to invest directly in the development and commercialisation of our own intellectual property.

We are presently in discussions with a number of third parties with respect to Biotech Capital potentially acquiring the development and commercialisation rights to some exciting and novel technologies in both the medical device and therapeutic areas. I look forward to providing further updates to shareholders as may be appropriate.

In concluding I would like to take this opportunity to thank the entire Biotech Capital team for their tremendous energy and commitment to our goals over the last year. As individuals and as a team they constantly strive to go well beyond the ordinary.

Biotech Capital.

My thanks also to our Directors, who are always readily available and engaged in the business, and finally to our shareholders we gratefully acknowledge your ongoing support of the company and our shared vision.

A handwritten signature in black ink, appearing to read 'Richard Treagus', with a stylized flourish at the end.

Dr. Richard Treagus
Chairman